Icotrokinra治疗中重度斑块状银屑病1年持久性:III期ICONIC-ADVANCE 1和2结果
ICONIC-ADVANCE 1和2两项III期试验随机1505例中重度斑块状银屑病成人,接受icotrokinra 200mg、安慰剂(第16周转icotrokinra)或deucravacitinib 6mg(第24周转icotrokinra)每日一次。第24-52周,约70-75%达IGA 0/1和PASI 90,约50%达IGA 0和PASI 100;第16周达标者约85-90%在第52周维持应答,安全性与安慰剂相似且至52周无安全信号。
要点
- icotrokinra 200mg每日一次至52周维持高清除率:约70-75%达IGA 0/1和PASI 90。
- 第16周达清除/几乎清除者约85-90%在第52周维持应答。
- 从安慰剂或deucravacitinib转换至icotrokinra后应答率提升,与初治组相当。
核心结论
- 每日一次icotrokinra在中重度斑块状银屑病成人中至第52周提供稳健持久的皮损清除和症状改善,无安全信号。
研究设计与样本
- 两项III期、安慰剂和阳性对照试验ICONIC-ADVANCE 1(NCT06143878)和ICONIC-ADVANCE 2(NCT06220604),分别按2:1:2和4:1:4随机分组。
- 共随机1505例中重度斑块状银屑病成人(分别为774例和731例),接受icotrokinra 200mg、安慰剂(第16周转icotrokinra)或deucravacitinib 6mg(第24周转icotrokinra)每日一次。
主要发现
- 第24-52周,随机接受icotrokinra者中约70-75%达IGA 0/1和PASI 90,约50%达IGA 0和PASI 100。
- 第16周达清除/几乎清除者中约85-90%在第52周维持应答;ss-IGA 0/1和患者报告结局亦持久至第52周。
- 从安慰剂或deucravacitinib转换至icotrokinra者应答率提升,与随机接受icotrokinra者至第52周相当。
- 不良事件特征至第16周与安慰剂相似,至第24周低于deucravacitinib,至第52周无安全信号。
临床怎么用
- icotrokinra可作为中重度斑块状银屑病每日一次口服系统治疗,提供长期稳健疾病控制和良好安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Icotrokinra, a targeted oral peptide, precisely blocks the interleukin-23 receptor. In two phase III moderate-to--severe plaque psoriasis trials, ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), icotrokinra provided significantly higher skin clearance rates vs. placebo at week 16 and deucravacitinib at weeks 16 and 24. OBJECTIVES: To evaluate the clinician- and patient-reported outcomes (PROs) for participants who received icotrokinra in the ICONIC-ADVANCE 1 and ADVANCE 2 phase III clinical trials. METHODS: ICONIC-ADVANCE 1 and 2 randomized (2 : 1 : 2 and 4 : 1 : 4, respectively) adults with moderate-to-severe plaque psoriasis to icotrokinra 200 mg, placebo (transition to icotrokinra at week 16) or deucravacitinib 6 mg once daily (transition to icotrokinra at week 24). Outcomes assessed through week 52 included proportions of participants achieving Investigator Global Assessment (IGA) 0/1 (with ≥ 2-grade improvement from baseline), Psoriasis Area and Severity Index (PASI) 90, IGA 0, PASI 100, scalp-specific IGA (ss-IGA) 0/1, several well-established PROs, and adverse events (AEs). RESULTS: ICONIC-ADVANCE 1 and 2 randomized 1505 participants (774 and 731, respectively). Skin clearance rates among participants randomized to icotrokinra increased through week 24 and were durable through week 52, with approximately 70-75% exhibiting clear/almost clear skin (IGA 0/1, PASI 90) and approximately 50% demonstrating completely clear skin (IGA 0, PASI 100) during weeks 24-52. Among participants achieving clear/almost clear skin at week 16, around 85-90% maintained response at week 52. Response rates for ss-IGA 0/1 and PROs were also durable through week 52. Participants who transitioned from placebo or deucravacitinib to icotrokinra exhibited increasing response rates that were comparable to participants randomized to icotrokinra through week 52. The AE profile was similar to placebo through week 16 and showed lower AE rates than deucravacitinib through week 24; no safety signals were observed through week 52. CONCLUSIONS: Once-daily icotrokinra provided robust, durable skin clearance and symptom improvement, with no safety signals, through week 52 in adults with moderate-to-severe plaque psoriasis. Participants transitioning from placebo or deucravacitinib to icotrokinra achieved similar increased response rates to participants who were randomized to icotrokinra through week 52. Our findings support icotrokinra as a systemic therapy with long-term robust disease control and a favourable safety profile. Psoriasis is an inflammatory skin condition, which causes thick, scaly skin plaques that may itch or hurt. Psoriasis is caused by high levels of certain immune system signalling molecules. One such molecule is interleukin (IL)-23. Injected medicines that block IL-23 help to treat moderate-to-severe plaque psoriasis. Icotrokinra is a tablet taken by mouth that precisely blocks the IL-23 receptor. This approach aims to provide the benefits of highly efficacious IL-23-targeted therapy in a convenient form. ICONIC-ADVANCE 1 and 2 are two global clinical trials that studied icotrokinra. Adults with moderate-to-severe plaque psoriasis received icotrokinra, a placebo (for 16 weeks) or deucravacitinib (for 24 weeks). After 16 or 24 weeks, all trial participants received icotrokinra throughout 52 weeks. More participants receiving icotrokinra from the start achieved clear or almost clear skin compared with participants who received placebo at 16 weeks, or participants who received deucravacitinib at 16 and 24 weeks. The skin clearance rates remained high throughout 52 weeks. Many participants who received icotrokinra reported better quality of life. They also reported improvements in their psoriasis symptoms, including itch. By week 52, participants who changed from placebo or deucravacitinib to icotrokinra showed similar improvements to those who received icotrokinra from the beginning. The rates of side-effects were similar for participants who received icotrokinra and placebo at week 16. These participants reported fewer side-effects than those treated with deucravacitinib at week 24. No safety concerns with icotrokinra arose through 52 weeks. Icotrokinra may offer a convenient treatment option for people with moderate-to-severe plaque psoriasis. It has the advantage of being provided in a once-daily pill, with a favourable safety profile.
引用
- Stein Gold L, Armstrong AW, Soung J, et al. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials. Br J Dermatol. 2026. PMID: 42397072. doi:10.1093/bjd/ljag264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。